Your session is about to expire
← Back to Search
CagriSema Dose 2 for Type 2 Diabetes (REIMAGINE 1 Trial)
REIMAGINE 1 Trial Summary
This trial will investigate whether a new experimental medicine called CagriSema can help people with type 2 diabetes reduce their blood sugar and body weight. Participants will be randomly assigned to receive either C
REIMAGINE 1 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.REIMAGINE 1 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is the enrollment process currently ongoing for this research study?
"According to information found on clinicaltrials.gov, recruitment for this study is currently closed. The trial was listed on 3/19/2024 and last modified on 3/15/2024. However, amidst the inactive status of this particular trial, there are a substantial number of 1464 alternative studies available for patient enrollment at present."
In how many diverse venues is this experimental examination currently being conducted?
"This clinical trial is conducted at Valley Clinical Trials, Inc. in Northridge, Texas; Southern California Dermatology in Santa Ana, Florida; and Northeast Clinical Research of San Antonio in San Antonio, Massachusetts among 33 additional sites nationwide."
What are the safety considerations related to Cagrisema Dose 1 in patients?
"Based on our evaluation, the safety rating of Cagrisema Dose 1 is categorized as a level 3. This classification stems from its Phase III trial status, indicating existing efficacy data and robust safety records."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger